Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 20/20 | 1.00 |
| ▸ | ADAM17 | P78536 | 10/20 | 1.00 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 1.00 |
| ▸ | TNF | P01375 | 1/20 | 1.00 |
| ▸ | MMP2 | P08253 | 1/20 | 1.00 |
| ▸ | MMP3 | P08254 | 1/20 | 1.00 |
| ▸ | MMP9 | P14780 | 1/20 | 1.00 |
| ▸ | MMP8 | P22894 | 1/20 | 1.00 |
| ▸ | MMP13 | P45452 | 1/20 | 1.00 |
| ▸ | MMP14 | P50281 | 1/20 | 1.00 |
| ▸ | ADAMTS1 | Q9UHI8 | 1/20 | 1.00 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL136238 | 1.00 | MMP1 (1.00) | MMP1ADAM17ADAMTS4TNFMMP2 | |
| SCHEMBL136239 | 1.00 | MMP1 (1.00) | MMP1ADAM17ADAMTS4TNFMMP2 | |
| SCHEMBL5892681 | 0.92 | MMP1 (1.00) | MMP1ADAM17ADAMTS4TNFMMP2 | |
| SCHEMBL5892683 | 0.92 | MMP1 (1.00) | MMP1ADAM17ADAMTS4TNFMMP2 | |
| SCHEMBL5892700 | 0.92 | MMP1 (1.00) | MMP1ADAM17ADAMTS4TNFMMP2 | |
| SCHEMBL5892954 | 0.92 | MMP1 (1.00) | MMP1ADAM17ADAMTS4TNFMMP2 | |
| SCHEMBL25833 | 0.91 | MMP1 (1.00) | MMP1ADAM17ADAMTS4TNFMMP2 | |
| SCHEMBL138144 | 0.91 | MMP1 (1.00) | MMP1ADAM17ADAMTS4TNFMMP2 | |
| SCHEMBL138143 | 0.91 | MMP1 (1.00) | MMP1ADAM17ADAMTS4TNFMMP2 | |
| SCHEMBL17479343 | 0.91 | MMP1 (0.83) | MMP1ADAM17ADAMTS4TNFMMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 419 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037404-B2 | Human monoclonal antibodies against EphA4 and their use | THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2024-07-16 | — | — | US | disclosed |
| EP-2534153-B2 | SALTS AND POLYMORPHS OF 8-FLUORO-2-{4-[(METHYLAMINO}METHYL]PHENYL}-1,3,4,5-TETRAHYDRO-6H-AZEPINO[5,4,3-CD]INDOL-6-ONE | PFIZER (US) | 2024-05-22 | — | — | EP | disclosed |
| US-20240109862-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER INC. | 2024-04-04 | — | — | US | disclosed |
| EP-4166558-A1 | SALTS AND POLYMORPHS OF 8-FLUORO-2-{4- [(METHYLAMINO)METHYL]PHENYL}-1 ,3,4,5-TETRAHYDRO-6H-AZEPINO[5,4,3- CD]INDOL-6-ONE | Pfizer Inc. (US) | 2023-04-19 | — | — | EP | disclosed |
| EP-3473271-B1 | HUMAN MONOCLONAL ANTIBODIES AGAINST EPHA4 AND THEIR USE | US GOV HEALTH & HUMAN SERVICES (US) | 2022-07-20 | — | — | EP | disclosed |
| US-11078288-B2 | Methods and compositions for treating tumor diseases | AMGEN INC. (US) | 2021-08-03 | — | — | US | disclosed |
| US-11078260-B2 | Antibodies to endoplasmin and their use | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2021-08-03 | — | — | US | disclosed |
| US-20210171645-A1 | HUMAN MONOCLONAL ANTIBODIES AGAINST EPHA4 AND THEIR USE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2021-06-10 | — | — | US | disclosed |
| US-10934360-B2 | Human monoclonal antibodies against EPHA4 and their use | THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2021-03-02 | — | — | US | disclosed |
| EP-3177320-B1 | HUMAN MONOCLONAL ANTIBODIES AGAINST EPHA4 AND THEIR USE | US GOV HEALTH & HUMAN SERVICES (US) | 2021-01-06 | — | — | EP | disclosed |
| US-20020004514-A1 | Anticancer compound and enantiomer separation method useful for synthesizing said compound | PFIZER PRODUCTS INC. | 2002-01-10 | — | — | US | disclosed |
| WO-2001098277-A2 | SUBSTITUTED BICYCLIC DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER PRODUCTS INC. (US) | 2001-12-27 | — | — | WO | disclosed |
| WO-2001094353-A1 | THIOPHENE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PRODUCTS INC. (US) | 2001-12-13 | — | — | WO | disclosed |
| EP-1150973-A1 | HETEROARYL-SUBSTITUTED QUINOLIN-2-ONE DERIVATIVES USEFUL AS ANTICANCER AGENTS | Pfizer Products Inc. (US) | 2001-11-07 | — | — | EP | disclosed |
| WO-2001053289-A1 | ANTICANCER COMPOUND AND ENANTIOMER SEPARATION METHOD USEFUL FOR SYNTHESIZING SAID COMPOUND | PFIZER PRODUCTS INC. (US) | 2001-07-26 | — | — | WO | disclosed |
| US-6258824-B1 | TREATMENT OF HYPERPROLIFERATIVE DISEASES, SUCH AS CANCERS, IN MAMMALS. THIS INVENTION ALSO RELATES TO A PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH COMPOUNDS. | PFIZER INC. | 2001-07-10 | — | — | US | disclosed |
| EP-1106612-A1 | Quinoline derivatives useful for inhibiting farnesyl protein transferase | Pfizer Products Inc. (US) | 2001-06-13 | — | — | EP | disclosed |
| WO-2001040217-A1 | NOVEL BENZOIMIDAZOLE DERIVATIVES USEFUL AS ANTIPROLIFERATIVE AGENTS | PFIZER PRODUCTS INC. (US) | 2001-06-07 | — | — | WO | disclosed |
| WO-2001034574-A1 | STABLE POLYMORPH OF N-(3-ETHYNYLPHENYLAMINO)-6,7-BIS(2-METHOXYETHOXY)-4-QUINAZOLINAMINE HYDROCHLORIDE, METHODS OF PRODUCTION, AND PHARMACEUTICAL USES THEREOF | OSI PHARMACEUTICALS, INC. (US) | 2001-05-17 | — | — | WO | disclosed |
| WO-2000047574-A1 | HETEROARYL-SUBSTITUTED QUINOLIN-2-ONE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PRODUCTS INC. (US) | 2000-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240109862-A1 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | GPR119, INSR, LYAR | MMP1 3955/4885ADAM17 4460/4885ADAMTS4 4820/4885 |
| US-20020004514-A1 | Anticancer compound and enantiomer separation method useful for synthesizing said compound | HCCS, MCL1, CDKN1A | MMP1 4245/4885ADAM17 2019/4885ADAMTS4 4578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.